Published in final edited form as:

Leuk Res. 2013 December ; 37(12): . doi:10.1016/j.leukres.2013.09.013.

The fusion partner specifies the oncogenic potential of *NUP98* fusion proteins

Jesslyn Saw¹, David J. Curtis¹, Damian J. Hussey², Alexander Dobrovic³, Peter D. Aplan⁴, and Christopher I. Slape¹

¹Division of Blood Cancers, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC, Australia

²Department of Surgery, Flinders University, Flinders Medical Centre, Bedford Park, SA, Australia

³Ludwig Institute for Cancer Research, Heidelberg, VIC, Australia; Department of Pathology, University of Melbourne, Melbourne, VIC, Australia

⁴Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Abstract

NUP98 is among the most promiscuously translocated genes in hematological diseases. Among the 28 known fusion partners, there are two categories: homeobox genes and non-homeobox genes. The homeobox fusion partners are well-studied in animal models, resulting in HoxA cluster overexpression and hematological disease. The non-homeobox fusion partners are less well studied. We created transgenic animal models for three *NUP98* fusion genes (one homeobox, two non-homeobox), and show that in this system, the *NUP98*-homeobox fusion promotes self-renewal and aberrant gene expression to a significantly greater extent. We conclude that homeobox partners create more potent *NUP98* fusion oncogenes than do non-homeobox partners.

Keywords

NUP98; homeobox; HOX; leukemia; translocation

Introduction

Chromosomal translocations in human leukemia are a source of novel oncogenes termed fusion genes, which encode fusion proteins combining the properties of two distinct

© 2013 Elsevier Ltd. All rights reserved.

Corresponding author: Christopher I. Slape, christopher.slape@monash.edu, Postal address: Department of Biochemistry and Molecular Biology, Building 77, Monash University, Melbourne 3800, Australia, Phone +61 3 9902 9257.

Conflict of interest statement

CIS and PDA receive royalties from the National Institutes of Health Technology Transfer Office for the invention of the *NUP98*-HOXD13 mice. The remaining authors declare no competing financial interests.

Authors' Contribution

JS and CS performed experiments and prepared the first draft. DJC, PDA and CS conceived and designed the study. DJH and AD provided critical reagents and revised the article. CS prepared the final draft of the manuscript. All authors edited and approved the final manuscript.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

proteins. Some genes are involved in multiple oncogenic fusion proteins with distinct partner genes, indicating that the properties of that gene are generally oncogenic if deregulated, or that there are multiple mechanisms by which oncogenic fusion proteins involving the gene can act. The *Nucleoporin 98 (NUP98)* gene encodes a protein which is normally involved in nuclear transport, but is also recurrent in many different chromosomal translocations in myelodysplastic syndrome (MDS) and acute leukemia[1]. It is among the most promiscuous known fusion gene partners, having been identified in fusion genes with 28 distinct partner genes. The estimated frequency of *NUP98* translocations in human leukemia has been recently revised upward, with modern molecular techniques leading to superior detection of these translocations[2, 3]. Further, the *NUP98-JARID1A* fusion represents a functionally distinct subclass of AML, suggesting that other *NUP98* fusions may do the same [2]. Understanding the leukemic activity of the various *NUP98* fusions is therefore of increasing importance.

NUP98 fusion partner genes can be broadly broken into two groups: homeobox genes and non-homeobox genes. Homeobox genes are transcription factors defined by the conserved “homeodomain” DNA-binding domain, and this DNA-binding domain is conserved in the fusion proteins with *NUP98*, of which there are at least ten [1]. This retention of the DNA-binding domain suggests a transcriptional regulatory mechanism for the *NUP98*-homeobox fusion proteins. Indeed in the case of the *NUP98-HOXA9 (NHA9)* fusion, this has been directly shown[4]. For the non-homeobox fusion proteins, of which there are at least eighteen [1], an overarching mechanism has been slower to emerge. Recent work has suggested that regulation of gene expression by chromatin reading and/or writing via indirect DNA binding is the mechanism for at least some non-homeobox fusion partners[1, 5, 6], although not all eighteen have the requisite domains for this activity.

We have previously reported the generation of the *NUP98-HOXD13 (NHD13)* transgenic mouse[7]. Created using the cloned fusion gene from a human MDS under a transgenic vav promoter[8], the *NHD13* mouse develops an MDS by the age of five months (100% penetrance) and an acute leukemia from the age of six months (60% penetrance). The only other reported example of a transgenic *NUP98* fusion is also a *NUP98*-homeobox fusion; the *NHA9* transgenic mouse is also reported to develop acute myeloid leukemia (AML), albeit at a lower penetrance and later age (22% by 15 months)[9]. No transgenic models of *NUP98*-non-homeobox fusion genes have been reported, but there are numerous reports of retrovirally-transduced bone marrow models of these genes, which generally result in myeloproliferative neoplasms or AML [5, 6, 10].

We sought to investigate the relative oncogenic activity of homeobox and non-homeobox *NUP98* fusion genes using similar techniques. To this end, we selected three *NUP98* fusion genes to study: *NUP98-HOXD13 (NHD13)* [11], *NUP98-TOP1 (NT)*[12] and *NUP98-RAP1GDS1 (NRG)*[13]. All of these fusion genes retain the 5' portion of *NUP98*, including the FG repeats responsible for karyopherin docking during nuclear transport[14] (Figure 1A). The 3' portion of *HOXD13* that is retained includes the homeodomain, a DNA binding domain. The 3' portion of *TOP1 (Topoisomerase I)* that is retained includes the core, linker and catalytic domains used in the protein's normal function of unwinding DNA superstructures [15]. The 3' portion of the *NRG* fusion retains the entirety (bar the first methionine) of *RAP1GDS1 (RAP1 GTP-GDP dissociation stimulator 1)*, including the armadillo domain. *RAP1GDS1* encodes a protein known as smgGDS, which is involved in guanine nucleotide exchange activity[16]. We created transgenic mouse models expressing *NT* and *NRG* from the same vav promoter used in the creation of the *NHD13* mouse. We compare phenotype, aberrant gene expression profiles and abnormal self-renewal activity in each of these models to determine the relative oncogenic potency of each of these genes.

Material and methods

Generation of transgenic mice

The *NUP98-HOXD13* mice have been described previously (Lin et al 2005). We used the pZVNHD13 vector used in the generation of these mice as the basis for generating the *NUP98-TopoisomeraseI* (NT) and *NUP98-RAP1GDS1* (NRG) mice. Full-length NT and NRG cDNAs were PCR amplified and cloned into the pZVNHD13 vector, replacing the *NHD13* sequence in the vector. These resultant vectors (pZVNT and pZVNRG) were sequenced to verify the constructs. The pZVNT and pZVNRG plasmids were digested with PmeI, and the insert containing 5' and 3' vav regulatory elements and the respective fusion gene cDNA were purified by agarose gel electrophoresis and Qiagen gel purification, using the manufacturer's recommendations. The construct was microinjected into zygotes obtained from C57Bl6 mice. Founders were identified using a human *NUP98* probe, and offspring were genotyped by PCR amplification of the respective transgene from tail biopsy DNA. Lines were maintained by mating with wild-type C57bl6 mice. All animal experiments were approved by the Animal Care and Use Committee at NCI or the Animal Ethics Committee at Monash University.

Real time PCR

Total DNA was prepared from tail biopsies using standard techniques. Total RNA was prepared from FACS-sorted LK cells by using the Trizol (Invitrogen) reagent according to the manufacturer's instructions. In the case of the hNUP98 PCR, RNA was DNase-treated using the Turbo DNA-free kit (Ambion Life Technologies). cDNA was transcribed from 1 ug of RNA using the Roche Transcriptor kit according to the manufacturer's instructions. PCR reactions using the Promega GoTaq mastermix were performed on a LightCycler480 (Roche). PCR cycling conditions included an initial denaturation (95°C 60 sec) followed by 95°C 10 sec, 55°C 10 sec and 72°C 30 sec. Data were analyzed using the Roche LightCycler 480 software.

FACS Analysis

BM samples were flushed from femora and tibiae into PBS containing 2% fetal bovine serum (FBS). Antibodies and other reagents for staining were obtained from BD Pharmingen (San Diego, CA): B220 and CD4 as fluorescein isothiocyanate (FITC) conjugates; SCA (E13-161.7) and CD8 (53-6.7) as phycoerythrin (PE) conjugates; CD4 (RM4-5) and c-KIT (2B8) as allo-phycoerythrin (APC) conjugates; and biotinylated Mac-1 (M1/70), Gr-1 (RB6-8C5), Ter-119, B220 (RA3-6B2) and CD3 (145-2C11). Second-stage reagents were Streptavidin (SAv) Peridinin Chlorophyll Protein Complex (PerCP). Cell viability was measured by exclusion of propidium iodide (PI; Sigma, St Louis, CA). FACS analysis was performed using a FACSCalibur or LSR-II instrument (BD Biosciences). Cell sorting was performed using a FACS Aria instrument (BD Biosciences).

Blood Cell Counts

Blood samples were collected into EDTA-coated tubes and full blood counts were determined on an Advia 120 Automated Hematology Analyzer.

Hematopoietic Progenitor Assays

BM cells were seeded at a density of 5×10^4 cells per 35 mm dish in semi-solid agar for GM colony growth. Cultures were incubated at 37°C in 10% CO₂ for 7 days, stained with acetylcholinesterase and counted. Replating was performed using unstained plates. Colonies were extracted using a pipette tip, the cells disaggregated in 50 ul of PBS, and each individual colony was then replated in semi-solid agar in the same conditions. For replating assays,

BM cells were seeded at a density of 10^5 cells per 35 mm dish in methylcellulose. Cultures were incubated at 37°C in 10% CO₂ for 7 days and colonies counted. Whole plates were harvested and washed, and 10^5 cells were seeded into fresh methylcellulose dishes.

Results

Generation of *NT* and *NRG* transgenic mice

We have previously reported the cloning of the *NUP98-TOP1* (*NT*)[12] and *NUP98-RAP1GDS1* (*NRG*)[13] fusion gene cDNAs from patients with therapy-related myelodysplastic syndrome bearing the t(11;20)(p15;q11) and T-cell acute lymphocytic leukemia bearing the t(4;11)(q21;p15), respectively (Figure 1A). We cloned these cDNAs into the identical *vav* vector used for generation of *NHD13* transgenic mice[7] (Figure 1B). Following pronuclear injection, we identified four founder mice for the *NT* transgene which were able to transmit the transgene through the germline, as determined by PCR genotyping. Three founders were identified for the *NRG* line which were capable of transmitting the transgene to their offspring. We examined both transgenes to ensure they were expressed, and found them to be expressed exclusively in the hematopoietic compartment (data not shown). To narrow our study, we chose one founder from each of the *NT* and *NRG* lines to follow, selecting the one with the highest expression in the marrow.

We examined the relative copy number of each transgene to ensure comparability between the lines. This was achieved by Q-PCR for the shared portion of the human *NUP98* gene, using intron-spanning amplicons to ensure that amplification was restricted to the transgenes. To verify this, the endogenous murine *Nup98* gene did not amplify from the wild-type mouse. This Q-PCR was normalised using an unrelated endogenous genomic Q-PCR (of the *Gata4* locus). The *NT* line contained approximately four times the number of copies of the transgene as the *NRG* and *NHD13* lines (Figure 1C). To investigate transgene expression level, we performed Q-PCR with primers specific for the retained portion of the human *NUP98* common to all three transgenes. We examined expression in Lin- Kit+ (LK) progenitors. Species specificity was confirmed by the lack of amplification from wild type mice. The transgenes in *NHD13* and *NRG* mice were expressed at comparable levels, with the *NT* mice demonstrating approximately half the level of expression.

Phenotype of *NT* and *NRG* mice

NHD13 mice developed hematological phenotype of anemic, lymphopenia and thrombocytopenia by the age of 6 months[7]. In contrast, *NT* and *NRG* mice exhibit normal blood counts at six months of age (Figure 2A), and no anemia, lymphopenia or thrombocytopenia emerge as *NT* and *NRG* mice are aged out to 600 days (data not shown).

NHD13 mice have decreased progenitor cells as defined either by FACS staining for the LKS population or functionally by colony assay (CFU-GM) due to increased apoptosis [17]. Consistent with the normal blood counts, numbers of LKS (Figure 2B) and CFU-GM (Figure 2C) in the *NT* and *NRG* mice were normal. Examination of mature lineages and progenitors at 12 months of age also revealed no differences between *NT* or *NRG* mice and wild type littermates (data not shown).

The thymic CD4/CD8 profiles of *NT* and *NRG* mice were normal (Figure 2D&E), indicating that differentiation is not impaired in these cells, in contrast to the *NHD13* phenotype which shows an increase in CD4/CD8 double negative (DN) thymocytes, consistent with previous results [18].

Aged cohorts of each strain were monitored for the development of acute leukemia. As previously reported, *NHD13* mice developed leukemia beginning prior to 6 months of age,

with 62% (13/21) having established leukemia by the age of 12 months. Of these, nine (43%) leukemias had features of AML and four (19%) had features of T-ALL. The remaining eight mice that survived to 12 months were severely cytopenic but without apparent acute disease, in keeping with the known phenotype of *NHD13* mice. In contrast, by 600 days of age only 2/29 (7%) *NT* and 4/22 (18%) *NRG* mice developed AML (Figure 3A), as determined by infiltration of spleen and marrow with Mac-1+ cells (Figure 3B). This disease onset late, with the earliest occurring at 451 days of age. All wild type mice remained healthy through 600 days. These data indicate that *NT* and *NRG* have oncogenic potential, but are weaker oncogenes than *NHD13*.

***NT* and *NRG* fusion proteins are less potent inducers of self-renewal and homeobox gene expression**

To investigate the self-renewal properties of these progenitor cells, we performed serial replating of individual CFU-GM colonies. *NHD13* CFU-GM colonies were able to form secondary colonies with a frequency of ~ 50% while wild type CFU-GMs replated with a frequency of ~ 2%, indicating a clear increase in self-renewal in *NHD13* CFU-GMs in this assay. *NRG* CFU-GMs had a replating efficiency of 10%, while *NT* CFU-GM colonies showed no increased replating ability above wild type (Figure 4A). We also conducted standard replating experiments in which 10⁵ cells were replated from each plate. In this assay, *NHD13* colonies replated indefinitely as previously shown [7], both *NT* and *NRG* colonies replated on the fourth but not the fifth replating, while wild type cells were not able to produce colonies after two replatings (Figure 4B).

Gene expression profiling of *NHD13* progenitor (Lin- Kit+; LK) cells indicated that *NHD13* induces high levels of expression of numerous *Hox* genes[17]. We examined the relative expression in *NT* and *NRG* LK cells of four *Hox* genes that are overexpressed in *NHD13* LK cells (*Hoxa4*, *Hoxa5*, *Hoxa9* and *Hoxb5*), to determine if failure to induce *Hox* gene expression could be a molecular explanation for the weak oncogenic potential of *NT* and *NRG*. Indeed, only *Hoxb5* was significantly overexpressed in *NRG* LK cells, and none of the four genes were overexpressed in *NT* LK cells (Figure 4B–E). In addition, expression of the homeobox gene *Pbx3* [19], an important co-factor for the *Hox* genes[20] and which is also overexpressed in *NHD13* LK cells, was not increased in *NT* or *NRG* LK cells (Figure 4F).

Discussion

NUP98 forms fusion genes with 28 known partner genes in human MDS and leukemia. These partner genes fall into two clear categories; ten are homeobox transcription factors, and the remainder comprise a set of unrelated genes, none of which are known transcription factors[1]. The only noted commonality they share is the presence of at least one coiled-coil domain[21].

In the present study, we insert two non-homeobox *NUP98* fusion genes, *NT* and *NRG*, into a transgenic system identical to that previously used to generate the *NHD13* mouse model, and find that the two non-homeobox fusions are substantially less potent in this system. While oncogenic potential in transgenic mice can be affected by the type of promoter, mouse strain and transgene copy number, these factors are not likely to be resulting in the phenotypic differences seen in this study because all strains were generated using the same *vav* promoter construct, copy number was similar or higher in the two non-homeobox models, expression at the RNA level was comparable in all three models, and all strains were generated and maintained on a C57BL/6J background.

Phenotypic disease was much less penetrant in both the *NT* and *NRG* mice. There was no evidence of a “pre-malignant” phenotype as there is in the *NHD13* mice, with peripheral

blood counts remaining normal throughout life in the majority of animals. In late age, 2 of 29 *NT* mice and 4 of 22 *NRG* mice developed acute leukemia. This penetrance was greatly reduced in comparison to the 62% of acute leukemia at 365 days of age in the *NHD13* cohort. Onset of the disease was also much later in the *NT* and *NRG* mice, with no disease apparent prior to 400 days of age. Taken together, we conclude that *NT* and *NRG* are less potent oncogenes in this assay than is *NHD13*.

The cellular effect of most transcription factor fusion proteins is to block differentiation and increase self-renewal[22]. A standard assay for hematopoietic progenitor cell self-renewal is agar colony replating. We use a colony recloning assay as well as the more standard replating assay. Both assays showed that *NRG* myeloid progenitors have increased self-renewal capacity, but significantly less than those from *NHD13* mice. Cells from *NT* mice showed aberrant self-renewal ability in the standard assay but not in the colony recloning assay, suggesting a mild self-renewal advantage. We conclude that both *NT* and *NRG* cells have an increased renewal capability compared to wild type cells, but not to the same extent as do *NHD13* cells. *NUP98*-homeobox gene fusions have been widely demonstrated to upregulate expression of the *HOXA* cluster [1, 19], in a manner similar to many *MLL* fusion genes [23]. Recently, evidence has been presented that *NUP98-NSD1*[5], *-PHF23* and *-JARID1A*[6] cause *HOXA* cluster overexpression by induction of histone modification changes. Here, we show that two other non-homeobox fusion partners of *NUP98* (*RAP1GDS* and *TOP1*) have much weaker oncogenic potential than the homeobox fusion partner *HOXD13*. We propose that this is due to an inability of these two fusions to activate the *HOXA* gene cluster required for enhanced self-renewal of progenitors. *HOX* genes are expressed at high levels in hematopoietic precursors, and expression is gradually extinguished as cells mature (reviewed in [24]). Increased expression of *HOX* genes is common in both MDS and AML, and is a driving factor in aberrant self-renewal in these diseases[25]. The measurably increased self-renewal induced by *NRG* compared to *NT* is consistent with the increased expression of at least one *Hox* gene (*Hoxb5*) in *NRG* but not *NT* progenitors.

Our results differ from those of a previous study which used bone marrow transduction to enforce expression of *NT* [10]. The mice in this study developed AML with 100% penetrance and a median survival of 233.5 days. Possible explanations for the enhanced oncogenic potential in the retroviral system compared to our transgenic system include higher expression of the fusion gene. We have made every effort to ensure that the transgenes are expressed at similar levels, but can not rule out the possibility that different levels of each fusion protein may be present. A more attractive hypothesis to explain the difference between the transgenic and retroviral systems is that cooperative oncogenic hits arise from retroviral insertion effects. This latter hypothesis is supported by the mono- or oligoclonal basis of disease in the original study, and that at least one such cooperative hit resulting from retroviral insertion was identified [10].

With a lesser increase in self-renewal than that of *NHD13* mice, *NT* and *NRG* mice have a decreased propensity to develop leukemia. The lower penetrance and increased latency of disease suggests a greater requirement for additional mutations, which may combine with *NT* or *NRG* to increase self-renewal, alongside mutations required to overcome other barriers to transformation. Alternatively, the greater amount of aberrant self-renewal in the *NHD13* mice may create an environment in which these latter mutations occur with higher frequency, while the environment in *NT* or *NRG* mice may promote these mutations at a lesser rate. While the precise oncogenic mechanism remains to be determined, we have shown that, in this transgenic system, there are different levels of oncogenic potency among *NUP98* fusion oncogenes.

Acknowledgments

We thank Lionel Feigenbaum of the NCI Transgenic core facility for the generation of the mice, animal facility staff for animal care, and Geza Paukovics, Michael Thomson and Jeanne Le Massurier for flow cytometric sorting. This research was supported by the National Health and Medical Research Council of Australia, the Cancer Council of Victoria and the Intramural Research Program of the National Institutes of Health, National Cancer Institute.

References

1. Gough SM, Slape CI, Aplan PD. NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. *Blood*. 2011; 118:6247–57. [PubMed: 21948299]
2. de Rooij JD, Hollink IH, Arentsen-Peters ST, van Galen JF, Berna Beverloo H, Baruchel A, et al. NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. *Leukemia*. 2013
3. Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Pratcorona M, Abbas S, Kuipers JE, et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. *Blood*. 2011; 118:3645–56. [PubMed: 21813447]
4. Kasper LH, Brindle PK, Schnabel CA, Pritchard CE, Cleary ML, van Deursen JM. CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity. *Mol Cell Biol*. 1999; 19:764–76. [PubMed: 9858599]
5. Wang GG, Cai L, Pasillas MP, Kamps MP. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. *Nat Cell Biol*. 2007; 9:804–12. [PubMed: 17589499]
6. Wang GG, Song J, Wang Z, Dormann HL, Casadio F, Li H, et al. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. *Nature*. 2009; 459:847–51. [PubMed: 19430464]
7. Lin YW, Slape C, Zhang Z, Aplan PD. NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. *Blood*. 2005; 106:287–95. [PubMed: 15755899]
8. Ogilvy S, Metcalf D, Print CG, Bath ML, Harris AW, Adams JM. Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. *Proc Natl Acad Sci U S A*. 1999; 96:14943–8. [PubMed: 10611317]
9. Iwasaki M, Kuwata T, Yamazaki Y, Jenkins NA, Copeland NG, Osato M, et al. Identification of cooperative genes for NUP98-HOXA9 in myeloid leukemogenesis using a mouse model. *Blood*. 2005; 105:784–93. [PubMed: 15454493]
10. Gurevich RM, Rosten PM, Schwieger M, Stocking C, Humphries RK. Retroviral integration site analysis identifies ICSBP as a collaborating tumor suppressor gene in NUP98-TOP1-induced leukemia. *Experimental hematology*. 2006; 34:1192–201. [PubMed: 16939812]
11. Raza-Egilmez SZ, Jani-Sait SN, Grossi M, Higgins MJ, Shows TB, Aplan PD. NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia. *Cancer Res*. 1998; 58:4269–7. [PubMed: 9766650]
12. Ahuja HG, Felix CA, Aplan PD. The t(11;20)(p15;q11) chromosomal translocation associated with therapy-related myelodysplastic syndrome results in an NUP98-TOP1 fusion. *Blood*. 1999; 94:3258–61. [PubMed: 10556215]
13. Hussey DJ, Nicola M, Moore S, Peters GB, Dobrovic A. The (4;11)(q21;p15) translocation fuses the NUP98 and RAP1GDS1 genes and is recurrent in T-cell acute lymphocytic leukemia. *Blood*. 1999; 94:2072–9. [PubMed: 10477737]
14. Griffis ER, Altan N, Lippincott-Schwartz J, Powers MA. Nup98 is a mobile nucleoporin with transcription-dependent dynamics. *Molecular biology of the cell*. 2002; 13:1282–97. [PubMed: 11950939]
15. Wang JC. DNA topoisomerases. *Annual review of biochemistry*. 1996; 65:635–92.
16. Mizuno T, Kaibuchi K, Yamamoto T, Kawamura M, Sakoda T, Fujioka H, et al. A stimulatory GDP/GTP exchange protein for smg p21 is active on the post-translationally processed form of c-Ki-ras p21 and rhoA p21. *Proc Natl Acad Sci U S A*. 1991; 88:6442–6. [PubMed: 1907371]

17. Slape CI, Saw J, Jowett JB, Aplan PD, Strasser A, Jane SM, et al. Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome. *Blood*. 2012; 120:2475–83. [PubMed: 22855610]
18. Choi CW, Chung YJ, Slape C, Aplan PD. A NUP98-HOXD13 fusion gene impairs differentiation of B and T lymphocytes and leads to expansion of thymocytes with partial TCRB gene rearrangement. *J Immunol*. 2009; 183:6227–35. [PubMed: 19841179]
19. Novak RL, Harper DP, Caudell D, Slape C, Beachy SH, Aplan PD. Gene expression profiling and candidate gene resequencing identifies pathways and mutations important for malignant transformation caused by leukemogenic fusion genes. *Experimental hematology*. 2012; 40:1016–27. [PubMed: 22885519]
20. Li Z, Zhang Z, Li Y, Arnovitz S, Chen P, Huang H, et al. PBX3 is an important cofactor of HOXA9 in leukemogenesis. *Blood*. 2012
21. Hussey DJ, Dobrovic A. Recurrent coiled-coil motifs in NUP98 fusion partners provide a clue to leukemogenesis. *Blood*. 2002; 99:1097–8. [PubMed: 11822362]
22. Gilliland DG, Tallman MS. Focus on acute leukemias. *Cancer Cell*. 2002; 1:417–20. [PubMed: 12124171]
23. Nguyen AT, Taranova O, He J, Zhang Y. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9- mediated leukemogenesis. *Blood*. 2011; 117:6912–22. [PubMed: 21521783]
24. Argiropoulos B, Humphries RK. Hox genes in hematopoiesis and leukemogenesis. *Oncogene*. 2007; 26:6766–76. [PubMed: 17934484]
25. Thorsteinsdottir U, Mamo A, Kroon E, Jerome L, Bijl J, Lawrence HJ, et al. Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. *Blood*. 2002; 99:121–9. [PubMed: 11756161]

Figure 1. Creation of NT and NRG transgenic mice

A) Schematic showing the retained domains of each fusion partner gene. In each case the upper gene is NUP98, with the GLFG repeat domains shown in black, and the lower gene is the fusion partner. In all fusions, the 5' portion of NUP98 is fused to the 3' portion of the partner. For HoxD13 the black box represents the homeodomain, for Top1 the boxes represent (left to right) the core, linker and catalytic domains, and for Rap1GDS1 the black boxes represent the armadillo domains. The vertical black line represents the fusion point. B) Structure of the vav vector used to generate the transgenic mice. C) Real-time PCR data indicating the relative signal obtained for a transgene-specific NUP98 amplicon from bone marrow obtained from each of the three mouse lines and wild type mice. D) Real-time PCR

data indicating the signal (relative to HPRT signal) obtained for a transgene-specific NUP98 amplicon from LK cells obtained from each of the three mouse lines and wild type mice.

Figure 2. Pre-leukemic phenotype of NT and NRG mice

A) Hematocrit of mice of each genotype. B) Percentage of Lin- Kit⁺ Sca⁺ cells in the bone marrow of mice of each genotype (n=5). C) Colonies formed in CFU-GM assays per 5×10^4 cells seeded (n=6). D) Representative CD4 vs CD8 FACS plot from thymus of mice of each genotype. E) Quantitation of CD4⁻ CD8⁻ cells from thymus of mice of each genotype (n=3). * indicates p<0.05; ** indicates p<0.01; *** indicates p<0.001. All assays performed on mice at 5 months of age.

Figure 3. Leukemic phenotype of NT and NRG mice

A) Survival curve for cohorts of wild type (n=25), NHD13 (n=21), NT (n=29) and NRG (n=22) mice. NHD13 mice were not monitored beyond 12 months of age. Other cohorts were monitored for 600 days. B) Representative FACS profiles of leukemias shows Mac vs B220 profile of spleen. Image on the left is a representative wild-type mouse, middle image is an NT leukemia, and image on the right is an NRG leukemia.

Figure 4. The self-renewal ability and Hox gene expression signature of NT and NRG mice
 A) Number of colonies that were successfully re-plated, from the 50 colonies that were picked from each plate (n=6). B) Number of colonies obtained from successive replating of 10^5 cells (n=3). C–F) Expression of HoxA4, HoxA5, HoxA9, HoxB5 and Pbx3, shown relative to the expression of Hprt, is shown for mice of each genotype. * indicates $p < 0.05$; ** indicates $p < 0.01$; *** indicates $p < 0.001$; **** indicates $p < 0.0001$. All assays performed on mice at 5 months of age.